The FDA has been a bunch of busy bees with new approvals:1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved for AML.3. Zenoctuzumab gets an FDA approval for cholangiocarcinoma with an efficacy patient population = 194. T-DXd is a good drug and continues to pile on FDA approvals5. Adjuvant atezolizumab in bladder cancer is approved in conjunction with ctDNA serial monitoring to determine who gets treatmentCheck out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm